Leerink Partners Initiates Coverage On Nautilus Biotechnology with Outperform Rating, Announces Price Target of $4
Leerink Partners analyst Puneet Souda initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Outperform rating and announces Price Target of $4.
An expert analyst started watching Nautilus Biotechnology and thinks it's worth checking out, setting a target price of $4. When smart analysts start paying attention to a smaller company, it can mean they see something interesting growing there—worth noticing, but not a guarantee of anything.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.